{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:45:17Z","timestamp":1782636317791,"version":"3.54.5"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"am","delay-in-days":711,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP20lm0203011"],"award-info":[{"award-number":["JP20lm0203011"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP20am0101087"],"award-info":[{"award-number":["JP20am0101087"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004219","name":"Paul Scherrer Institut","doi-asserted-by":"publisher","award":["20191094"],"award-info":[{"award-number":["20191094"]}],"id":[{"id":"10.13039\/501100004219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004219","name":"Paul Scherrer Institut","doi-asserted-by":"publisher","award":["20191134"],"award-info":[{"award-number":["20191134"]}],"id":[{"id":"10.13039\/501100004219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2145"],"award-info":[{"award-number":["JPMJSP2145"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006699","name":"High Energy Accelerator Research Organization","doi-asserted-by":"publisher","award":["2021G011"],"award-info":[{"award-number":["2021G011"]}],"id":[{"id":"10.13039\/501100006699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006699","name":"High Energy Accelerator Research Organization","doi-asserted-by":"publisher","award":["2019G016"],"award-info":[{"award-number":["2019G016"]}],"id":[{"id":"10.13039\/501100006699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bmc.2023.117370","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T22:13:14Z","timestamp":1686262394000},"page":"117370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-0339","authenticated-orcid":false,"given":"Mineyuki","family":"Mizuguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5362-8606","authenticated-orcid":false,"given":"Takeshi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Toyooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117370_b0005","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2023.117370_b0010","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1021\/bi952501g","article-title":"The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid","volume":"35","author":"Lai","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2023.117370_b0015","doi-asserted-by":"crossref","first-page":"12119","DOI":"10.1021\/bi00096a024","article-title":"Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity","volume":"32","author":"McCutchen","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2023.117370_b0020","doi-asserted-by":"crossref","first-page":"13527","DOI":"10.1021\/bi00041a032","article-title":"Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease","volume":"34","author":"McCutchen","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2023.117370_b0025","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1073\/pnas.93.13.6302","article-title":"A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis","volume":"93","author":"Jenne","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2023.117370_b0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0014-5793(97)01398-7","article-title":"The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution","volume":"418","author":"Quintas","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmc.2023.117370_b0035","doi-asserted-by":"crossref","first-page":"32943","DOI":"10.1074\/jbc.274.46.32943","article-title":"The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis","volume":"274","author":"Quintas","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0040","doi-asserted-by":"crossref","first-page":"27207","DOI":"10.1074\/jbc.M101024200","article-title":"Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants","volume":"276","author":"Quintas","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bmc.2023.117370_b0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2047-9158-3-19","article-title":"Recent advances in transthyretin amyloidosis therapy","volume":"3","author":"Ueda","year":"2014","journal-title":"Transl Neurodegener."},{"key":"10.1016\/j.bmc.2023.117370_b0055","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bmc.2023.117370_b0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3390\/genes12070955","article-title":"Ocular Involvement in Hereditary Amyloidosis","volume":"12","author":"Minnella","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bmc.2023.117370_b0065","first-page":"361","article-title":"Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G)","volume":"148","author":"Vidal","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bmc.2023.117370_b0070","first-page":"351","article-title":"Leptomeningeal amyloid and variant transthyretins","volume":"148","author":"Benson","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bmc.2023.117370_b0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/brain\/122.2.183","article-title":"Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis","volume":"122","author":"Brett","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.bmc.2023.117370_b0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jns.2008.05.014","article-title":"A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis","volume":"272","author":"Nakagawa","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bmc.2023.117370_b0085","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nrl.2012.12.006","article-title":"Leptomeningeal amyloidosis due to A25T TTR mutation: a case report","volume":"29","author":"Llull","year":"2014","journal-title":"Neurologia"},{"key":"10.1016\/j.bmc.2023.117370_b0090","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2023.117370_b0095","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2023.117370_b0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug","volume":"421","author":"Johnson","year":"2012","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2023.117370_b0105","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1107\/S0907444996003046","article-title":"Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution","volume":"52","author":"Wojtczak","year":"1996","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117370_b0110","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2023.117370_b0115","first-page":"165","article-title":"Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy","volume":"2","author":"Buxbaum","year":"2012","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"10.1016\/j.bmc.2023.117370_b0120","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.bmc.2023.117370_b0125","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/DDDT.S289772","article-title":"Drug discovery and development in rare diseases: taking a closer look at the tafamidis story","volume":"15","author":"Burton","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2023.117370_b0130","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.bmc.2023.117370_b0135","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.033","article-title":"Failure of tafamidis to halt progression of Ala36Pro TTR oculomeningovascular amyloidosis","volume":"27","author":"Salvi","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.bmc.2023.117370_b0140","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2023.117370_b0145","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117370_b0150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bmc.2023.117370_b0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.bmc.2023.117370_b0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2023.117370_b0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2023.117370_b0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.bmc.2023.117370_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116550","article-title":"Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors","volume":"53","author":"Reum Han","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0180","doi-asserted-by":"crossref","first-page":"14673","DOI":"10.1021\/acs.jmedchem.2c01195","article-title":"Development of a highly potent transthyretin amyloidogenesis inhibitor: design, synthesis, and evaluation","volume":"65","author":"Pinheiro","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0185","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.bmc.2010.12.050","article-title":"A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin","volume":"19","author":"Choi","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0190","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1021\/acs.jmedchem.5b00544","article-title":"Enthalpic forces correlate with the selectivity of transthyretin-stabilizing ligands in human plasma","volume":"58","author":"Iakovleva","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0195","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0200","doi-asserted-by":"crossref","first-page":"e0153529","DOI":"10.1371\/journal.pone.0153529","article-title":"Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer","volume":"11","author":"Iakovleva","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117370_b0205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/74082","article-title":"Rational design of potent human transthyretin amyloid disease inhibitors","volume":"7","author":"Klabunde","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.bmc.2023.117370_b0210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/jm030347n","article-title":"Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis","volume":"47","author":"Adamski-Werner","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0215","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.bmc.2023.117370_b0220","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bmc.2023.117370_b0225","first-page":"1","article-title":"CSF\/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis","volume":"30","author":"Takahashi","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.bmc.2023.117370_b0230","doi-asserted-by":"crossref","first-page":"14344","DOI":"10.1021\/acs.jmedchem.1c00823","article-title":"Repositioning of the anthelmintic drugs bithionol and triclabendazole as transthyretin amyloidogenesis inhibitors","volume":"64","author":"Yokoyama","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0235","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.3390\/ijms21197166","article-title":"Repurposing benzbromarone for familial amyloid polyneuropathy: a new transthyretin tetramer stabilizer","volume":"21","author":"Cotrina","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2023.117370_b0240","doi-asserted-by":"crossref","unstructured":"Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha Castelar Pinheiro G, Dos Santos Paiva E. Benzbromarone in the treatment of gout. Adv Rheumatol. 2019, 59, 37.","DOI":"10.1186\/s42358-019-0080-x"},{"key":"10.1016\/j.bmc.2023.117370_b0245","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF01727785","article-title":"Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone","volume":"66","author":"Walter-Sack","year":"1988","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.bmc.2023.117370_b0250","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/BF00185609","article-title":"Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite","volume":"71","author":"de Vries","year":"1993","journal-title":"Clin Investig"},{"key":"10.1016\/j.bmc.2023.117370_b0255","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3109\/00498259309059452","article-title":"Metabolism of benzbromarone in man: structures of new oxidative metabolites, 6-hydroxy- and 1'-oxo-benzbromarone, and the enantioselective formation and elimination of 1'-hydroxybenzbromarone","volume":"23","author":"De Vries","year":"1993","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bmc.2023.117370_b0260","first-page":"45","article-title":"Biliary excretion of benzbromarone and its hydroxilated main metabolites in humans","volume":"3","author":"Walter-Sack","year":"1998","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.bmc.2023.117370_b0265","article-title":"Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof","author":"Endou","year":"2009","journal-title":"United States Patent."},{"key":"10.1016\/j.bmc.2023.117370_b0270","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2133\/dmpk.DMPK-10-NT-040","article-title":"Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes","volume":"25","author":"Uchida","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bmc.2023.117370_b0275","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/bjo.2009.158048","article-title":"Transthyretin levels in the vitreous correlate with change in visual acuity after vitrectomy","volume":"93","author":"Van Aken","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.bmc.2023.117370_b0280","doi-asserted-by":"crossref","first-page":"e48042","DOI":"10.1371\/journal.pone.0048042","article-title":"Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia","volume":"7","author":"Maetzler","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117370_b0285","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ejmech.2016.02.074","article-title":"A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition","volume":"121","author":"Sim\u00f5es","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0290","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1021\/jm1015022","article-title":"Developing Potent Human Uric Acid Transporter 1 (hURAT1) Inhibitors","volume":"54","author":"Wempe","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0295","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1021\/jm401832j","article-title":"Crystal structures of human transthyretin complexed with glabridin","volume":"57","author":"Yokoyama","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0300","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.1021\/jm500997m","article-title":"Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin","volume":"57","author":"Yokoyama","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0305","doi-asserted-by":"crossref","first-page":"13570","DOI":"10.1038\/srep13570","article-title":"Discovery of \u03b3-mangostin as an amyloidogenesis inhibitor","volume":"5","author":"Yokoyama","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2023.117370_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116292","article-title":"Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis","volume":"44","author":"Kitakami","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0315","doi-asserted-by":"crossref","first-page":"37732","DOI":"10.1074\/jbc.M204514200","article-title":"CH...O hydrogen bonds at protein-protein interfaces","volume":"277","author":"Jiang","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0320","doi-asserted-by":"crossref","first-page":"16789","DOI":"10.1073\/pnas.0407607101","article-title":"Halogen bonds in biological molecules","volume":"101","author":"Auffinger","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2023.117370_b0325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pro.2201","article-title":"Halogen bonding (X-bonding): a biological perspective","volume":"22","author":"Scholfield","year":"2013","journal-title":"Protein Sci"},{"key":"10.1016\/j.bmc.2023.117370_b0330","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1021\/acs.chemrev.5b00484","article-title":"The halogen bond","volume":"116","author":"Cavallo","year":"2016","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2023.117370_b0335","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.1021\/acs.jmedchem.8b01453","article-title":"Halogens in protein-ligand binding mechanism: a structural perspective","volume":"62","author":"Shinada","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0340","doi-asserted-by":"crossref","first-page":"16218","DOI":"10.1021\/acs.jmedchem.2c00511","article-title":"Chlorinated naringenin analogues as potential inhibitors of transthyretin amyloidogenesis","volume":"65","author":"Mizuguchi","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0345","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1021\/acs.jmedchem.0c02268","article-title":"Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117370_b0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1046-5928(03)00069-X","article-title":"Expression of a synthetic gene encoding human transthyretin in Escherichia coli","volume":"30","author":"Matsubara","year":"2003","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.bmc.2023.117370_b0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117370_b0360","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117370_b0365","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117370_b0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"Sebaugh","year":"2011","journal-title":"Pharm Stat"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623002183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623002183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:50:41Z","timestamp":1778791841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":74,"alternative-id":["S0968089623002183"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117370","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117370"}}